Fujitsu America, Inc.

Fujitsu America BioSciences Group Announces Global Licensing Deal with GPC Biotech AG for BioMedCAChe™ Automated Docking Software

Leading cancer therapeutic discovery and development company GPC Biotech to implement Fujitsu's desktop automated docking platform at sites in U.S. and Europe

Westwood, MA, January 11, 2005 — The BioSciences Group of Fujitsu America, Inc., a worldwide leader in providing innovative and reliable solutions to experimental scientists, today announced a global licensing agreement with GPC Biotech AG, a global cancer drug discovery and development company, for Fujitsu's BioMedCAChe suite of automated docking and molecular modeling software. GPC Biotech will implement BioMedCAChe in its Waltham, Massachusetts and Martinsried/Munich, Germany sites.

"We are delighted that GPC Biotech has chosen BioMedCAChe as their docking solution," said Dr. Michael J. McManus, Vice President of the BioSciences Group at Fujitsu America. "Our mission is to develop and provide automated solutions that experimental scientists can use to create powerful simulations right in the laboratory."

BioMedCAChe provides powerful tools to speed the drug discovery process by enabling scientists to predict and select better quality leads. Using BioMedCAChe, scientists can view, analyze and modify protein structures using interactive sequence and 3D structure editor windows. In addition, scientists can optimize proteins, dock ligands, and model reactions of molecules with tens of thousands of atoms, all on their desktop computers.

---

About Fujitsu America's BioSciences Group

BioSciences Group, a division of Fujitsu America, Inc., capitalizes on Fujitsu Limited's over 20 years of leadership in creating innovative and reliable solutions for helping experimental scientists overcome the challenges in their laboratory workflow. BioSciences Group solutions provide a framework for researchers to make in silico predictions about leads, targets, and interactions, and to validate these hypotheses experimentally. BioSciences Group offerings include the CAChe® suite of life sciences predictive modeling tools, the ActiveSite™ module for drug discovery lead-generation, and the BioServer™ massively parallel simulation server for genomics-based drug design. For more information, please see: us.fujitsu.com/biosciences.

---